Press Release Archives | Page 8 of 23

Oncotarget News

Figure 2: Immunoblot assessment of effects on cell-cycle, pro- and anti-apoptosis signaling events mediated by Sacituzumab govitecan plus platinum-based chemotherapeutics in human TNBC, SCLC, and UBC tumor-lines.

Sacituzumab Govitecan Plus Platinum-based Chemotherapy in Breast, Bladder, and Lung Carcinomas

March 4, 2024

these results support the rationale and potential for favorable clinical outcomes of combining SG therapy with platinum-based chemotherapeutics in solid tumors.”BUFFALO, NY- March 4, 2024 – A new research paper... read more

Oncotarget

BRCA1 and BRCA2 in a Cohort of Ovarian Cancer Patients From the Salento Peninsula

February 28, 2024

Ovarian cancer (OC) is the third most prevalent type of gynecologic cancer affecting women after cervical and uterine cancer [1]. It is also considered the most fatal of all gynecological... read more

Figure 7: Combined macroautophagy and CD95 death receptor signaling facilitate additional tumor cell killing by GZ17-6.02

Oncotarget

GZ17-6.02 With Bexarotene Kills Mycosis Fungoides Cells

February 26, 2024

The present studies were performed to extend our knowledge of GZ17-6.02 biology from that known in solid tumor cell types such as prostate cancer cells to liquid tumor cell... read more

Figure 1: From genome-wide CRISPR screen to the creation of combined predicting models.

Oncotarget

Combining Causal and Correlative Approaches to Discover Response Biomarkers to Paclitaxel

February 21, 2024

The discovery of predictive biomarkers to paclitaxel vulnerability [such] as SSR3 [signal sequence receptor 3] promises to significantly impact cancer treatment.”BUFFALO, NY- February 21, 2024 – A new research perspective... read more

Figure 1: Flowchart depicting patient selection.

Oncotarget

NTRK Gene Fusion in Papillary Thyroid Cancer: A Clinicogenomic Biobank and Record Linkage Study From Finland

February 19, 2024

Estimates of the frequency of NTRK gene fusion in large cohorts of patients with solid tumors come from a limited number of studies. [...]. We aimed to address this gap by... read more

Figure 4: Correlation matrix with numerous significant positive correlations.

Oncotarget

Genetic and Therapeutic Landscapes in Cohort of Pancreatic Adenocarcinomas Using NGS and Machine Learning

February 14, 2024

Our study was designed to build specific mutational and therapeutic landscapes of pancreatic cancer among the Russian population.”BUFFALO, NY- February 14, 2024 – A new research paper was published in... read more

Oncotarget

Differential Expression of Mad2 Gene in Human Esophageal Cancer

February 12, 2024

people of the northeastern region [of India] consume betel quid, consisting of raw areca nut [...]. People often swallow the entire betel-quid after chewing, which is believed to contribute to the... read more

Figure 1: Ruxolitinib exerts its anti-myeloma effects through several mechanisms.

Oncotarget

Evaluation of Ruxolitinib, a Janus Kinase Inhibitor, in Multiple Myeloma

February 7, 2024

the results of the studies presented in this review will hopefully provide the impetus for conducting additional preclinical and clinical studies to evaluate RUX in the setting of MM as... read more

Figure 1: A typical drug discovery and development strategy.

Oncotarget

Drug Discovery in Academia; Dumping in the Publication Landfill?

February 5, 2024

fruitful efforts to bring more drugs from bench to bedside could only be possible if we do not leave them ‘midway’!”BUFFALO, NY- February 5, 2024 – A new editorial paper... read more

Figure 2: BCAS1+ cells in diffuse gliomas are morphologically different from BCAS1+ cells in healthy brain tissue.

Oncotarget

BCAS1 Defines a Heterogeneous Cell Population in Diffuse Glioma Patients

January 31, 2024

this is the first study describing a BCAS1+ cell population in a large cohort of diffuse glioma patients.”BUFFALO, NY- January 31, 2024 – A new research paper was published in... read more